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Abstract Genomic microarray may detect susceptibility loci
(SL) for neurodevelopmental disorders such as autism and
epilepsy, with a yet unquantifiable risk for the fetus. The pre-
natal disclosure of susceptibility loci is a topic of much debate.
Many health care professionals fear that reporting susceptibil-
ity loci may put a psychological burden on pregnant couples.
It is our policy to disclose prenatal susceptibility loci as we
recognize them as actionable for prospective parents. The aim
of this report was to evaluate the psychological impact of
disclosing a prenatal diagnosis of susceptibility loci. The psy-
chological impact of disclosing susceptibility loci was evalu-
ated in the first patients who received such results. Eight out of
15 women who had a susceptibility locus disclosed and four
of their partners consented to share their experiences through a
telephonic evaluation (n=12). Follow-up time ranged from 3
to 15 months after their prenatal test result. The reporting of
susceptibility loci was initially ‘shocking’ for five parents
while the other seven felt ‘worried’. Ten out of 12 participants
indicated they would like to be informed about the suscepti-
bility locus again, two were unsure. Most had no enduring
worries. Participants unanimously indicated that pregnant
couples should have an individualized pre-test choice about
susceptibility loci (non)disclosure. We observed no negative
psychological impact with the prenatal diagnosis and disclo-
sure of SL on participants. A key factor in mitigating parental
anxiety with SL disclosure appears to be post-test genetic
counseling. Our report confirms that pregnant women and
their partners prefer an individualized choice regarding the
scope of prenatal testing.
Keywords Invasive prenatal diagnosis . Susceptibility loci .
VOUS . CNV . Psychological impact . Genomicmicroarray .
Uncertainty . Individualized choice
Introduction
Genomic microarray may detect more copy number variants
(CNVs) that cause clinically relevant abnormalities and gen-
erates results faster than conventional karyotyping (CK)
(Wapner and Jackson 2008; Wapner et al. 2012; Fiorentino
et al. 2011). Therefore, we use SNP array instead of conven-
tional karyotyping (CK) for routine cytogenetic analysis for
all indications since July 2012 (Srebniak et al. 2013; Van
Opstal et al. 2015). Next to known microdeletion syndromes
such as Prader-Willi syndrome, or Duchenne muscular dys-
trophy, array testing may also reveal susceptibility loci (SL)
for neurodevelopmental disorders. Susceptibility loci (SL)
were defined as following by Girirajan et al.: ‘SL are copy
number variants (CNVs) with an extreme phenotypic hetero-
geneity and/or of variable expressivity’ (Van Opstal et al.
2015; Girirajan et al. 2012; Srebniak et al. 2014, 2015) asso-
ciated with an unquantifiable risk of neurodevelopmental dis-
orders such as epilepsy, autism and psychiatric disorders and
can be found in about 1.4 % of fetuses without ultrasound
anomalies (Van Opstal et al. 2015; Srebniak et al. 2015). SL
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are often inherited from (apparently) unaffected parents, but
are more frequently detected in affected individuals as com-
pared to control populations (Srebniak et al. 2014; Kaminsky
et al. 2011; Rosenfeld et al. 2013; Srebniak 2013). Genetic
counseling in pregnancies where SL are found is challenging
as it is difficult to estimate the chance of expression and/or to
predict the phenotype because most likely a second hit like
another genetic or even non-genetic factor, like environment,
may also influence the expression of the phenotypes (Veltman
and Brunner 2010; Girirajan et al. 2010). Almost all informa-
tion about SL phenotypes and penetrance that is available is
based on postnatal ascertainment. There is currently no infor-
mation available about the development of children in whom a
SL was found prenatally.
The value of SNP array in fetuses who were prenatally
diagnosed with ultrasound anomalies has been widely accept-
ed (Wapner et al. 2012; Fiorentino et al. 2011), but its imple-
mentation for other indications has raised concerns among
health care professionals, causing much debate regarding the
disclosure of SL (de Jong et al. 2013; McGillivray et al. 2012;
Vetro et al. 2012). Some classify these CNVs as variants of
unknown clinical significance (VOUS) (Wapner et al. 2012),
but because of their association with an abnormal phenotype,
we have classified SL as pathogenic (Srebniak et al. 2014). In
our opinion, SL are different from VOUS because the pheno-
typic effect of VOUS is unknown, whereas for an SL the
association with a specific phenotype is known but has a high-
ly variable penetrance and expression.
It has been argued that pregnant couples may wish not to be
informed on findings of uncertain expression (Hillman et al.
2013) and that such findings should bewithheld in order not to
put burden on the pregnant couple (Rigter et al. 2013; de Jong
et al. 2014). It has also been said, both for susceptibility loci
and VOUS, that reporting them may create a false sense of
autonomy (Brady et al. 2013), because an overload of infor-
mation could deteriorate reproductive autonomy, or raise pos-
sible emotional harm such as distress (McGillivray et al.
2012). Some ethicists argued that genetic information of un-
clear meaning interferes with reproductive autonomy and
should not be provided for this reason (de Jong et al. 2014).
On the other hand, others argue that it is paternalistic to try
to prevent women from emotional harm and potential termi-
nation of a pregnancy, and that pregnant women are entitled to
be informed of all genetic information (McGillivray et al.
2012) and that better tools for dealing with uncertainty should
be developed (Vetro et al. 2012; Rigter et al. 2013; Wolf et al.
2008; Stark et al. 2013).
Although we are well aware of the burden that SL may
represent psychologically for the pregnant couple, for several
reasons we have chosen to disclose SL when prenatally de-
tected. Firstly, we consider most SL to be actionable during
and/or after pregnancy. For example, SL may be associated
with congenital heart disease and an expert ultrasound
examination during pregnancy can be offered. Secondly, if
neurodevelopmental problems occur (either early or late on-
set), rapid diagnostics and more adequate care may be mobi-
lized when parents have the knowledge of the SL (Govaerts
et al., manuscript in preparation) (Dababnah and Parish 2015).
Since we implemented SNP array for all indications, we
encountered 14 cases of SL in 1330 pregnancies without ul-
trasound abnormalities (Van Opstal et al. 2015). To date, no
patient experiences regarding the psychological impact of SL
on pregnant couples has been reported. To explore whether
disclosure of SL indeed puts a heavy burden on the parents
(McGillivray et al. 2012; Rigter et al. 2013; de Jong et al.
2014; Brady et al. 2013), we feel it is important to understand
how SL disclosure affects pregnant couples. We report on the
narratives of 12 parents’ experiences with a prenatally
disclosed SL.
Patients and Methods
Summary of the Standard Clinical Procedure
Pre-Test Counselling by a Senior Obstetrician
All patients undergoing invasive prenatal diagnosis (PND)
received pre-test counselling by a senior obstetrician and re-
ceived a patient information leaflet which specified that ‘all
pathogenic results will be reported’. Pregnant couples were
informed about array testing. The occasional occurrence of
unexpected findings was discussed. These could either be
pathogenic CNVs not related to the prior indication for inva-
sive testing or susceptibility loci (SL), Patients received no
detailed information regarding SL. Unexpected findings were
discussed, but there was no strong emphasis on SL as a cate-
gory of outcomes of invasive prenatal testing. SNP array test-
ing was performed as a first-tier diagnostic test as described
before (Srebniak et al. 2013; Van Opstal et al. 2015).
Disclosing the Prenatal Test Result
When a SL was diagnosed pregnant couples were contacted
directly by a clinical geneticist informing them that there was
no causative chromosomal abnormality found, but a deviant
finding that may require special attention. They were invited
for extensive post-test counseling available the next day. For
extensive information about our counseling methods and
pregnancy management, see Govaerts et al. (manuscript in
preparation), in short:
1. The nature of the particular SL was explained. Phenotypic
examples (including pictures) from the postnatal literature
were available.
1228 van der Steen et al.
2. An expert ultrasound examination was offered if the SL
was associated with structural abnormalities.
3. We offered targeted parental SNP array in all cases be-
cause knowing whether an SLwas inherited aided in eval-
uating the clinical implications of the SL within the
family.
4. The couples were informed about the possibility for early
postnatal intervention programs (www.mee.nl), and the
option to terminate the pregnancy was discussed.
5. The pregnant women and their partners were offered support
from a medical psychologist specialized in prenatal care.
Inclusion for the Psychological Evaluation
In this report we describe the experiences pregnant couples
had when a susceptibility locus was found after invasive ge-
netic testing, in the absence of ultrasound anomalies. Between
July 2012 and December 2013, 14 couples received a prenatal
diagnosis of a SL, and all of them were contacted. A clinical
geneticist contacted them and asked whether theywere willing
to share their experiences by phone in order to assess the
impact of disclosing a prenatal susceptibility locus. This inter-
view was part of aftercare in order to learn about the long term
psychological impact of SL disclosure in pregnancy. All pa-
tients proceeding with invasive prenatal testing, signed con-
sent for further follow up during pregnancy and after delivery.
Eight women and four of their partners agreed to share their
experiences, see Fig. 1 for the participants. The prenatal test-
ing indication and array findings in 8 fetuses of the parents
that took part in the interview are shown in Table 1. None of
the participants decided to terminate the pregnancy. The par-
ents of live born children reported no congenital anomalies or
dysmorphic features that were detected at birth. In Table 2,
array results are displayed with phenotype and incidences
based on the information the parents received. All couples
were offered psychological support in dealing with the out-
come after disclosure of SL, but none of them indicated they
wanted to make use of this.
The follow-up interview period between invasive PND and
the contact ranged between 3 and 18 months. The mean time
before the follow-up interview was 10 months after disclosure.
Three participants were still pregnant at the time of follow-up.
Measures
Consenting participants were approached for a follow-up in-
terview by phone, using semi-structured questions (mean du-
ration: 30 min). Women and their partners were interviewed
individually. In Table 3, all questions are summarized. All
interviews were transcribed verbatim and translated from
Dutch to English. Worries about the health and development
of the child were measured on a scale of 1 to 10 (1 - not at all to
10 - very much so).
Analysis
Qualitative analysis was performed on the answers of all par-
ticipants. A posteriori, three independent judges (SL; JV; SR)
categorized the answers to the open-ended questions (see
Table 4). Subsequently, the judges came to a consensus re-
garding which categories emerged from which questions. The
three judges independently assigned a dichotomous score (0
not present; 1 present) to each theme per question.
The observed inter-judge agreement varied between
α= .44 and α=1.00. The inter-judge reliability ranged from
acceptable to excellent, except for question 1, which had a
poor inter-judge reliability (α= .44) (Field 2009).
Results: Participant’s Narratives
Initial Experience when the SL was Disclosed
Qualitative analysis of the interviews showed that 7 out of 12
participants said they were ‘worried’, while the other 5 partic-
ipants said ‘it was real shock’ to hear about the SL.We provide
quotes to the answers by category. Participants marked with
an asterisk (*) were still pregnant during follow-up.
Question 1 and 2
What was it like for you when you were told about the SL
that was found? What was your first reaction?
Quotes of parents who were worried (7 out of 12)
14 couples with SL 
approached
8 participating 




2 couples refused 
participation
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‘It startled me, you just don’t want to hear that about
your baby. But I thought that our baby would develop
normally, maybe a bit slower than others, but healthy in
the end.’ (Participant 2, female)
‘It was unpleasant, because we thought everything
would be fine. Thus far, it appears as such.’
(Participant 4, male)
‘Wewere a little shocked at first, but we understood that
there was only a very small chance that something could
really be wrong. So we were not too worried.’
(Participant 6, male)
‘We were a bit upset the first days. When we had an
advanced ultrasound, everything looked normal, that
was a relief to us.’ (Participant 8, male)
‘It came very unexpectedly, I was a little overwhelmed,
but I wasn’t really, really alarmed.’ (Participant 10*,
female)
‘At first we were not too alarmed, because the
baby did not have Down syndrome. But we felt
the SL diagnosis was slightly worrisome, because
we did not know what we could expect at all.’
(Participant 11, male)
‘I was upset, because they could not tell me exactly how
high the risk of developing the clinical features was. I
just sat there stared at the geneticist and asked what it
was, and if it was dangerous.’ (Participant 12, female)
Quotes of parents who were shocked (5 out of 12)
Table 1 Participants’ age, sex, prenatal testing indication, time of follow up interview after disclosure and array results with mode of inheritance;
inherited from the mother (mat), de novo (dn), unknown in cases where parents refused testing (ukn)
Fetus Participant Age Sex Indication Follow-up (months) CNV (hg18) and inheritance
A 1 41 F AMA 9 15q11.2 (20,191,584-20,710,960) x1 mat
B 2 41 F aFTS 13 22q11.21 (17,249,767-19,959,004) x3 ukn
C 3 35 F aFTS 8 16p11.2 (29,548,278-30,171,562) x3 dn
4 35 M
D 5 23 F aFTS 15 15q11.2 (20,191,584-20,698,860) x1 ukn
6 33 M
E 7a 38 F AMA 4 15q11.2 (20,191,584-20,698,860) x1 dn
8 37 M
F 9a 37 F AMA 5 1q21.1 (144,959,767-146,307,651) x1 dn
G 10a 37 F aFTS 3 15q11.2 (20,070,582-20,718,150) x1 mat
11 38 M
H 12 39 F aFTS+AMA 15 3q29 (197,141,069-198,793,022) x3 mat
AMA advanced maternal age, aFTS abnormal first-trimester combined test
a Still pregnant during the interview
Table 2 Array results with incidences and postnatal ascertained phenotype
Array result N Incidences affected vs. controlsa Phenotypeb
15q11.2 microdeletion 4 0.60 % vs. 0.20 % (Cooper et al. 2011)
0.41 % vs. 0.37 % (Burnside et al. 2011)
Intellectual disability, neurodevelopmental delay,
behavioral problems, autism, facial dysmorphism
(Girirajan et al. 2012; Rosenfeld et al. 2013)
22q11.2 microduplication 1 0.21 % vs. 0.05 % (Kaminsky et al. 2011) Intellectual disability, hypotonia, hearing loss,
epilepsy, cardiac malformations, urinary tract
anomalies, growth retardation, facial
dysmorphism (Firth 1993)
16p11.2 microduplication 1 0.18 % vs. 0.02 % [32]
0.25 % vs. 0.04 % (Kaminsky et al. 2011)
Intellectual disability, schizophrenia, autism
(Kaminsky et al. 2011; Cooper et al. 2011)
3q29 microduplication 1 0.0005 % vs. 0.00009 % (Kaminsky et al. 2011) Intellectual disability, hypotonia, occular anomalies,
congenital heart defects (Ballif et al. 2008; Goobie et al. 2008)
1q21.1 microdeletion 1 0.35 % vs. 0.03 % (Kaminsky et al. 2011)
0.28 % vs. 0.018 % (Rosenfeld et al., 2013)
Intellectual disability, microcephaly, cardiac malformations,
cataracts, schizophrenia, renal and urinary
tract anomalies, autism (Rosenfeld et al. 2013)
a Incidences as counseled by the clinical geneticist in 2012–2013
b Phenotype: postnatal ascertained proband
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‘To us, it was very unclear at first. We heard some-
thing was wrong and it came as a shock, I was ner-
vous. When we had an appointment with the genet-
icist to talk about it, we understood that the risk was
quite low. I thought; ‘we’ll have to wait and see’,
but my husband was really worried. There was a
picture of a patient with the same deletion, clearly
showing something was wrong. This was very up-
setting to us. We didn’t really know what to do with
the provided information. I wasn’t expecting it and
did not think about the possibility of this kind of
outcome when we engaged in prenatal diagnosis,
only about the possibility of a trisomy. Maybe our
older daughter has this deletion too, but she is a
healthy, normal girl.’ (Participant 1, female)
’That was a real shock. It was quite upsetting. We
thought;What is going to happen next? It was not a very
nice time.’ (Participant 3, female)
‘We were startled, it was quite something. But we were
informed of the possibility of such results.’ (Participant
5, female)
‘Unpleasant. It came as a shock. We did an amniocen-
tesis hoping to hear that everything is alright, and then
this susceptibility locus came as a test result. I was very
emotional.’ (Participant 7*, female)
‘That was a real shock. It was not clear what was wrong,
that made me worry a lot. The more I thought about it,
the more worried I became. I had a lot of questions. I
kind of panicked. Luckily, we had an appointment with
the geneticist the next day. After that, I felt calmer.’
(Participant 9*, female)
Question 3: How do you Feel About the SL at This Very
Moment?
Quotes of parents that do not think about it often anymore
(11 out of 12)
‘I don’t think about it too much now.’ (Participant 2,
female)
‘I don’t think about it anymore. I think I just have a
normal, healthy son.’ (Participant 3, female)
‘I don’t look back on it. I gave birth to a healthy son.
‘(Participant 4, female)
‘I like to think that nothing is wrong. At the moment, I
don’t see any reason to think there is. ‘(Participant 5,
male)
‘During pregnancy I was worried about other physical
abnormalities. But now that I gave birth, I am not wor-
ried anymore.’ (Participant 5, female)
‘I don’t think about the SL anymore. I think I coped with
the information quite well.’ (Participant 6, male)
‘Most abnormalities were excluded with expert ultra-
sound examinations. We are only unsure of other
Table 3 Open-ended questions about the psychological impact of
prenatal SL disclosure
1. What was it like for you when you were told about the SL that was
found?
2. What was your first reaction?
3. How do you feel about the SL at this very moment?
4. Would you choose to be informed of SL again?
5. Do you think that pregnant women should have a choice regarding the
disclosure of SL?
6. Please indicate on a scale of 1 to 10 how worried you are about the
health/development of your child? (1 not worried at all - 10 very
worried)
Table 4 Overview of the answers of participants
Nr. 1 & 2. First reaction 3. How do you feel
about the SL now?
4. Would you choose
to be informed again?
5. Pregnant women





1 shocked stigma hesitant yes yes 2
2 shocked not thinking about it often yes yes yes 3
3 shocked not thinking about it often yes yes yes 3
4 worried not thinking about it often yes yes yes 2
5 shocked not thinking about it often yes yes yes 6
6 worried not thinking about it often yes yes yes 3
7a shocked not thinking about it often yes yes yes 7
8 shocked not thinking about it often yes yes yes 6
9a worried not thinking about it often hesitant yes yes 1
10a worried not thinking about it often yes yes yes 2
11 worried not thinking about it often yes yes yes 3
12 worried not thinking about it often yes yes yes 2
a Still pregnant during follow-up
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neurodevelopmental symptoms like behavioural prob-
lems. But we think everything will be fine.’
(Participant 7*, female)
‘After the expert ultrasound examinations we felt
reassured. The SL does not have to mean anything.’
(Participant 8, male)
‘I think the chance of expression of the SL is very small.
And if it will express itself, I think it will be mild and
actionable.‘(Participant 9*, female)
‘We will have to wait and see. I think it is nothing very
severe, since I carry it myself and do not have any symp-
toms. I am not too worried anymore.’ (Participant 10*,
female)
‘I think it might be something very mild. My wife has it
too. Maybe we will not even notice it. ‘(Participant 11,
male)
‘I do not see anything out of the ordinary regarding my
daughter at this point.’ (Participant 12, female)
Quote of a parent that experienced a stigma (1 out of 12)
‘It is something that you keep carrying with you. If she
behaves weirdly, then I immediately think that this be-
haviour is related to the SL. I also do not like the fact that
she already had a medical file before she even was
born.‘(Participant 1, female)
Question 4: Would you Choose to be Informed of SL Again?
Yes (10 out of 12 parents)
‘I want to know as much as possible. That is the reason I
chose for invasive prenatal diagnosis in the first place.’
(Participant 2, female)
‘Yes, even though it was distressful when we first heard
about the susceptibility locus. But if something might be
wrong with your child, you want to know about it.’
(Participant 4, male)
‘If I could choose, than I would like to know.’
(Participant 6, male)
‘Absolutely.’ (Participant 8, male)
‘Yes, I think so, because I prefer to know as much as
possible. ‘(Participant 10*, female)
‘Personally, I want to know everything, but I have an
academic degree. I can imagine that this kind of infor-
mation might be very confusing for people with a lower
educational level.’ (Participant 11, male)
‘Of course. Especially with regards to my advanced ma-
ternal age.’ (Participant 12, female)
Hesitant (2 out of 12 parents)
‘If I would get pregnant again, I might not want to know.
But in this pregnancy, I would not want to have missed
this information.’ (Participant 1, female)
‘It depends if it really matters. It did give us a lot of
stress, because we thought it was something very severe
at first. But I would be very curious in the future (next
pregnancy). A friend of mine, who had children at a
young age, did not have any genetic information about
her children at all. But her son has a neurodevelopmental
disorder and she did not know about it in advance. It can
be useful, because you know where it might come
from.‘(Participant 9*, female)
Worries about the health and development of the child
ranged from 2 to 7 on a 10-point scale, see Table 4. Most
participants mentioned that they now ‘just have the normal
worries any parent has’.
Discussion
Since it has been suggested that disclosure of SL may raise
emotional harm, we evaluated the psychological impact of
prenatal SL disclosure on pregnant couples. Women and their
partners initially felt worried and shocked. Most parents indi-
cated that the SL was not what they had expected from inva-
sive PND, however some recalled being informed on such
possibility during the pre-test counselling. Previous research
showed that pregnant women are hardly ever ready for receiv-
ing abnormal prenatal test results, even if they are well in-
formed (Bernhardt et al. 2013; Statham et al. 2000; Lalor
et al. 2009).
After their initial reaction, parents were confused and had a
high need for understanding these outcomes. Most were quite
alarmed by the phone call of the geneticist telling them that
there was a ‘peculiar finding that needed explanation’. All
parents indicated they appreciated that the post-test counsel-
ling was available the next day. Due to the highly variable
penetrance and expression, the meaning of the particular find-
ing remained uncertain for the parents. A few parents noted
that this uncertainty was stressful to them at first. However,
none of the parents made use of the psychological support
they were offered. None of the participants felt that a termina-
tion of pregnancy was a personal option for them. The inter-
views revealed that some parents adopted a wait-and-see pol-
icy; that they will have to wait and see in which way their child
will develop, with a positive state of mind. These parents
seemed less distressed when talking about their experiences.
Parents seemed to have recovered from their initial feelings,
and are now handling the knowledge about their child having a
SL fairly well. They seem to base this on a seemingly normal
phenotype, either after giving birth to a ‘normal appearing’ child
or with the reassurance of a ‘normal’ expert fetal ultrasound
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examination. At the moment of the follow-up interview (mean
time 10 months after disclosure), all born children had no con-
genital anomalies or dysmorphic features, but were still too
young to be examined for neurological development. None of
the fetuses had ultrasound anomalies. It is yet unknown whether
these childrenwill develop neurodevelopmental symptoms in the
future. Most parents did not have lingering worries regarding the
SL, except for one woman who experienced a stigma regarding
her seemingly normal and healthy born daughter. She told that
each time her daughter behaved aberrant, she immediately feared
it might be caused by the SL. This is something that is also
encountered in other studies on abnormal prenatal diagnoses,
even if the child has seemingly normal appearance (Bernhardt
et al. 2013). Other parents did not report stigma or enduring
worries about the child’s development, and mentioned they just
have ‘normal parental worries’ now. The interviewed parents
indicated feeling relieved after advanced ultrasound scanning
revealed no visible anomalies. We also found that parents, iden-
tified as SL carriers themselves, were in a way relieved, because
they had the feeling the child could be ‘normal’ like themselves.
These parents used themselves or their partner as a reference for
the interpretation of the SL in their fetus. The psychological
reaction reported by the individuals in our clinic may have been
milder as compared to the study of Bernhardt et al. (2013). In that
study, 23 participants were interviewed after disclosure of abnor-
mal prenatal microarray results, of which 9 were known patho-
genic results and 14 were variants of unknown clinical signifi-
cance (VOUS). As in our study Bernhardt observed that partic-
ipants initially felt shocked and worried, and had a problem with
understanding the uncertainty and unquantifiable risks.
Participants also shared a high need for support to manage and
understand their prenatal microarray results with the help of a
health care professional. However, in our study all women and
their partners were counselled by a senior geneticist, whereas in
the study of Bernhardt such support was not offered in all cases
which might explain to the enduring concerns and a lack of
support to manage decisions about termination of pregnancy
and/or birth.. In both Bernhardt’s study and our own, a key factor
in mitigating parental anxiety with SL disclosure appears to be
post-test genetic counseling (Bernhardt et al. 2013). However, in
our study, participants reactions seem milder. In the study of
Bernhardt, most participants indicated that they felt their test
result was ‘toxic knowledge’. In our study however, most partic-
ipants indicated that they ‘just have normal parental worries
now’, which clearly is a different outcome. The fact that all but
onewomanwould choose to be informed of prenatal SL again, is
a strong indicator of this.
Nearly all parents indicated they would want to be informed
of SL again if offered a choice. Parents who said they preferred to
know about SL, said they did so because they could quickly
mobilise adequate care if needed. For instance, if developmental
problems would occur, they could have access to early interven-
tions for i.e. autism. These findings are congruent with our earlier
study inwhichwe found that a vast majority of pregnant couples,
when offered a choice during pretest genetic counseling, opted
for SL disclosure (van der Steen et al. 2014). The parents we
discussed in this paper indicated that they would prefer to have a
choice regarding the (non)disclosure of SL. This paper supports
earlier reports (de Jong et al. 2013; van der Steen et al. 2014;
Boormans et al. 2010) that parents highly appreciate individual-
ized choice on the scope of prenatal testing. We have not ob-
served psychological burden, however it has to be taken into
account that the number of interviewed patients is small.
Furthermore, some participants were still pregnant at the time
of the interview. It is therefore difficult to make long-term con-
clusions. In our study, there was no distinction between prenatal
de novo and inherited findings, however, due to their different
nature parents might cope with them in another way. It would be
interesting to evaluate this. Research on a larger scale is much
needed to gain more insight in how pregnant couples are coping
with this type of prenatal information.
Conclusion
This small study showed that in our setting, there was no long-
term psychological burden for pregnant couples whose fetus
was diagnosed with a susceptibility locus. A key factor in
mitigating parental anxiety with SL disclosure appears to be
post-test genetic counseling. This paper confirms that parents
highly appreciate an individualized choice on the scope of
prenatal testing. We believe that if genomic microarray testing
is offered, a chance of the detection of results like susceptibil-
ity loci should be routinely mentioned during pre-test counsel-
ling. An opt-out possibility may be sufficient to support the
reproductive autonomy of pregnant couples.
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